Clinical trials: Liver Inflammation
Hepatitis, Hepatitis C
Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
This is a randomized, multicenter, 2-part, open-label trial of the combination regimen of grazoprevir (GZR [MK-5172]; 100mg), uprifosbuvir (UPR [MK-3682]; 450 mg) and ruzasvir (RZR [MK-8408]; 60 mg) with and without Ribavirin…
- Conditions
- Hepatitis, Hepatitis C, Digestive System Diseases, Flaviviridae Infections
- Trial name
- NCT02613403
- Testing
- MK-3682B, Ribavirin
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Infection
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)
This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who…
- Trial name
- NCT02105701
- Testing
- Grazoprevir + Elbasvir, Ribavirin
- Volunteers
- 420 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection
This study is to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with nosocomial genotype 1 hepatitis C virus (HCV) infection.
- Trial name
- NCT01924949
- Testing
- LDV/SOF
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Gilead Sciences
Diphtheria, Tetanus
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth
The purpose of this study is to describe the immunogenicity and safety of a novel DTaP- IPV- Hep B-PRT~T fully liquid combined hexavalent vaccine (Hexaxim™) administered at 6, 10 and 14 weeks of age in infants born to mothers…
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01948193
- Testing
- Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine
- Where
- 2 sites in India
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Liver Fibrosis
Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
Patients who have been treated for hepatitis C virus (HCV) infection who have failed to respond to anti-viral treatment are often concerned about their ongoing liver disease and are therefore looking for alternative treatments…
- Trial name
- NCT00180674
- Testing
- Warfarin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Imperial College London
Hepatitis C, Chronic
A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
This single arm study will provide treatment or re-treatment with PEGASYS as monotherapy or in combination with ribavirin (Copegus), to patients with chronic hepatitis C (CHC) who have participated in a previous Roche or Roche…
- Trial name
- NCT00800735
- Testing
- Pegylated-interferon alfa-2a, Ribavirin
- Where
- 23 sites in United States, Austria and 4 more
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Hepatocellular, Chronic Hepatitis B
The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)
The purpose of this study is to evaluate the effect of serum hepatitis B virus (HBV) DNA level on intrahepatic recurrence in locally treatable hepatocellular carcinomas (HCCs) related with HBV.
- Trial name
- NCT00397540
- Testing
- PEIT, RFTA
- Where
- South Korea
- Volunteers
- 145 people
- Sponsor
- Seoul National University Hospital
Hepatitis C Virus Infection
Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
This study will have two parts as follows: The PK Lead-in Phase of the study will evaluate the steady state pharmacokinetics (PK) and confirm the dose of sofosbuvir (SOF) in hepatitis C virus (HCV)-infected pediatric…
- Trial name
- NCT02175758
- Testing
- SOF, RBV
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients
The purpose of this study was to investigate antiviral activity, safety and pharmacokinetics of 5 days of monotherapy with BI 207127 in HCV genotype 1 (GT1) infected patients.
- Trial name
- NCT02176525
- Testing
- BI 207127 NA
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Haemophilus Influenzae Type b, Tetanus
Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers
The purpose of the study is to assess the immunogenicity and safety of three formulations of GSK Biologicals' GSK2036874A vaccine compared to Zilbrix™/Hib and Poliorix™ vaccines administered concomitantly, when administered as a…
- Conditions
- Haemophilus Influenzae Type b, Tetanus, Hepatitis B, Whole Cell Pertussis
- Trial name
- NCT01106092
- Testing
- GSK2036874A vaccine, Zilbrix™/Hib vaccine, Poliorix™
- Where
- Philippines
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C Infection
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin…
- Trial name
- ZIRCON (NCT02486406)
- Testing
- Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 64 people
- Sponsor
- AbbVie
Hepatitis C
Hepatitis C-Video vs. Brochure Education Delivery
The purpose of this study is to determine the most effective way to give patients information regarding hepatitis C virus infection.
- Trial name
- NCT04204447
- Testing
- Hepatitis C Educational Brochure, Hepatitis C Educational Video
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- State University of New York at Buffalo
Hepatitis B, Chronic Disease
Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
The purpose of this study is to evaluate antiviral activity and efficacy of entecavir (ETV) compared to adefovir in adults with chronic hepatitis B who have not been treated yet with an antiviral medicine.
- Trial name
- NCT00096785
- Testing
- entecavir, adefovir
- Where
- 24 sites in United States, Canada and 6 more
- Volunteers
- 69 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
The purpose of this study is to evaluate the efficacy of 4 different regimens of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV), defined as the proportion of patients with sustained virologic…
- Trial name
- PILLAR (NCT00882908)
- Testing
- TMC435, Ribavirin (R), PegIFNα-2a (P)
- Where
- 71 sites in United States, Australia and 11 more
- Volunteers
- 386 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C
The Boceprevir and Sildenafil Pharmacokinetics Study
This is a healthy volunteer study looking at the interactions between two drugs: boceprevir and sildenafil. New drugs are being developed to treat people with the chronic viral infection hepatitis C.
- Trial name
- NCT01499498
- Testing
- Sildenafil and Boceprevir
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Chronic Hepatitis B
Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod in participants with chronic hepatitis B (CHB) infection currently being treated with oral antivirals (OAV).
- Trial name
- NCT02166047
- Testing
- Vesatolimod
- Where
- 23 sites in United States, Canada and 4 more
- Volunteers
- 162 people
- Sponsor
- Gilead Sciences
HIV, Hepatitis B
Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests
This is a pilot, monocentric, prospective, randomized control trial looking at the use of rapid tests as a part of normal care. The investigators will be testing for hepatitis B virus (HBV), hepatitis C virus (HCV), and human…
- Conditions
- HIV, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular
- Trial name
- OPTISCREEN-III (NCT01790633)
- Testing
- ELISA, Rapid Test
- Where
- France
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Hepatitis, Safety and Tolerability
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
Background: People with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) tend to get infections more easily. This is because their immune systems are weakened.
- Trial name
- NCT03685708
- Testing
- HEPLISAV-B
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hepatitis B
Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®
This study was a comparative, randomized, double-blind clinical study of the efficacy and safety of Sci-B-Vac® (10 μg dose) and the Engerix-B® (20 μg dose) vaccines in two parallel groups of hepatitis B-naive healthy adult…
- Trial name
- NCT04209400
- Testing
- Sci-B-Vac®, Engerix-B®
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Chronic Hepatitis D Infection
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus (HBV) co-infected with hepatitis delta…
- Trial name
- NCT02637999
- Testing
- PEG IFN alfa-2a, Myrcludex B
- Volunteers
- 24 people
- Sponsor
- Hepatera Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.